cyclooxygenase

cyclooxygenase
Cytochrome c at English Wikipedia · CC BY-SA 3.0 · source
Name	Cyclooxygenase
EC number	1.14.99.1
Other names	Prostaglandin-endoperoxide synthase

cyclooxygenase

Cyclooxygenase is an enzyme family that catalyzes conversion of arachidonic acid to prostaglandin endoperoxides and is central to eicosanoid biosynthesis. Discovered through biochemical studies that involved investigators associated with Nobel Prize‑level research and institutions such as the National Institutes of Health and University of Oxford, the enzyme links inflammatory signaling studied in contexts like the Spanish flu era and modern immunology. Its clinical relevance spans therapeutics developed by companies like Pfizer and Merck & Co., and regulatory oversight by agencies such as the Food and Drug Administration.

Structure and isoforms

Cyclooxygenase exists mainly as two well characterized isoforms, COX‑1 and COX‑2, encoded by distinct genes first cloned in laboratories at institutions including the Scripps Research Institute and Harvard University. The proteins are homodimers with bifunctional domains resembling peroxidase enzymes studied in the tradition of Emil Fischer and structural determination performed by groups at the European Molecular Biology Laboratory and Brookhaven National Laboratory. High resolution structures obtained via techniques pioneered at Stanford University and the Max Planck Society revealed a membrane‑associated helix and an active site channel that bind fatty acid substrates, analogous to architectures resolved in proteins from the Protein Data Bank community. A third variant, COX‑3, was proposed based on alternative splicing work at Boston University and debated in literature from the Royal Society.

Catalytic mechanism and biochemical activity

The catalytic mechanism involves a cyclooxygenase reaction and a peroxidase reaction, steps elucidated in studies led by researchers affiliated with the American Association for the Advancement of Science and the Royal Society of Chemistry. The enzyme uses an iron‑containing heme prosthetic group reminiscent of heme enzymes characterized by investigators at the Max Planck Institute for Biophysics and the California Institute of Technology. Mechanistic proposals integrate radical chemistry principles discussed in conferences at the Royal Institution and workshops sponsored by the Gordon Research Conferences, and trace precedents to foundational work by Linus Pauling on enzyme catalysis. Kinetic and isotope labeling experiments from laboratories at Massachusetts Institute of Technology and Johns Hopkins University clarified steps producing prostaglandin G2 and prostaglandin H2 intermediates.

Physiological roles and tissue distribution

COX isoforms show differential tissue distribution studied in anatomical research traditions at Columbia University and University College London, with COX‑1 expressed constitutively in gastric mucosa, platelets and kidney tissues and COX‑2 inducible in inflammatory cells, endothelium and central nervous system sites investigated by teams at University of California, San Francisco and Karolinska Institute. Roles span homeostatic functions relevant to the World Health Organization’s priorities in public health, including maintenance of gastric integrity, platelet aggregation described in clinical studies at Mayo Clinic, and modulation of fever and pain responses explored by researchers at the Royal College of Surgeons.

Regulation and expression

Expression of cyclooxygenase isoforms is regulated by transcription factors and signaling pathways characterized in molecular biology programs at Cold Spring Harbor Laboratory and The Rockefeller University. Inducible expression of COX‑2 is driven by inflammatory mediators such as interleukins and tumor necrosis factor studied in work from the Pasteur Institute and Weizmann Institute of Science, and by mitogens and growth factors relevant to oncology research at Memorial Sloan Kettering Cancer Center. Post‑translational modifications and promoter polymorphisms were investigated in genetics centers at Imperial College London and the University of Tokyo.

Pharmacology and inhibition (NSAIDs and selective COX inhibitors)

Nonsteroidal anti‑inflammatory drugs (NSAIDs) like aspirin, ibuprofen and naproxen from pharmaceutical programs at Bayer and Johnson & Johnson inhibit cyclooxygenase activity; aspirin’s acetylation of a serine residue was characterized in biochemical studies linked to the legacy of Bayer AG and clinical evaluation overseen by the National Health Service (England). Selective COX‑2 inhibitors (coxibs) such as celecoxib and rofecoxib were developed and clinically trialed by teams at Pfizer and Merck & Co., with regulatory review by the European Medicines Agency and the Food and Drug Administration following cardiovascular safety concerns highlighted in randomized trials coordinated by research groups at Duke University and Johns Hopkins University Hospital. Drug design employed structural insights from crystallography groups at Yale University and computational chemistry centers at IBM Research.

Clinical significance and associated diseases

Aberrant cyclooxygenase activity contributes to inflammatory diseases treated in clinics at Cleveland Clinic and Mount Sinai Health System, to cardiovascular events evaluated in multicenter trials like those led by the Framingham Heart Study, and to cancer progression studied in oncology centers such as Dana‑Farber Cancer Institute and MD Anderson Cancer Center. COX‑2 overexpression is implicated in colorectal cancer research conducted at University of Edinburgh and in arthritis cohorts assessed by World Arthritis Foundation affiliates. Therapeutic strategies balancing gastrointestinal, renal and cardiovascular risks reflect guidance from bodies including the American Heart Association and European Society of Cardiology.

Evolution and genetic variants

Phylogenetic and comparative genomics studies tracing cyclooxygenase genes across vertebrates were performed by evolutionary biologists at Smithsonian Institution and the Natural History Museum, London, showing conservation of catalytic residues noted in analyses published by the National Academy of Sciences. Human genetic variants and promoter polymorphisms were investigated in population studies at UK Biobank and the 1000 Genomes Project, with associations to disease phenotypes reported by consortia including the International HapMap Project.

Category:Enzymes